Get access

Anti-β2-glycoprotein I antibodies

Authors

  • Rohan Willis,

    1. Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas
    2. Department of Microbiology, University of the West Indies, Kingston, Jamaica
    Search for more papers by this author
  • Silvia S. Pierangeli

    Corresponding author
    • Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas
    Search for more papers by this author

Address for correspondence: Silvia S. Pierangeli, APLS Laboratory, Brackenridge Hall 2.108, 301 University Boulevard, Galveston, TX 77555-003. sspieran@utmb.edu.

Abstract

Anti-β2-glycoprotein I (anti-β2GPI) antibodies are the main antiphospholipid antibodies, along with anticardiolipin and lupus anticoagulant, that characterize the autoimmune disease antiphospholipid syndrome (APS). While the exact physiological functions of β2GPI are unknown, there is overwhelming evidence that anti-β2GPI antibodies are pathogenic, contributing to thrombosis, pregnancy morbidity, and accelerated atherosclerosis in APS and systemic lupus erythematosus patients. The revelation that these antibodies play a central role in the pathogenesis and pathophysiology of APS has driven research to characterize the physiology and structure of β2GPI as well as the pathogenic effects of anti-β2GPI antibodies. It has also resulted in the development of improved testing methodologies for detecting these antibodies. In this review we discuss the characteristics of β2GPI; the generation, pathogenic effects, and standardized testing of anti-β2GPI antibodies; and the potential use of therapies that target the β2GPI/ anti-β2GPI interaction in the treatment of APS.

Ancillary